Concepedia

Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

Günter Emons, G Gorchev, Jalid Sehouli, Pauline Wimberger, Anne Stähle, Lars Hanker, Felix Hilpert, H. Sindermann, Carsten Gründker, Philipp Harter

Gynecologic Oncology · 2014 · 50 citations · 20 references

DOI

Concepts

References

20

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

Andreas du Bois, Eric Pujade‐Lauraine, Philipp Harter et al. · Cancer · 2009 · 1.6K citations · Full text

, , +16

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

, , +16

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer · 2011 · 619 citations

, , +17

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Lars Hanker, Sibylle Loibl, Nicole Burchardi et al. · Annals of Oncology · 2012 · 340 citations

, , +15